Company Filing History:
Years Active: 2019
Title: Innovations in Phototherapy: The Contributions of Randy Schwemmin
Introduction
Randy Schwemmin is an innovative inventor based in San Francisco, CA. He has made significant contributions to the field of medical technology, particularly in the treatment of neonatal hyperbilirubinemia. His work focuses on developing effective solutions that improve patient care and outcomes.
Latest Patents
Randy Schwemmin holds a patent for a phototherapy device designed for the treatment of hyperbilirubinemia. This device utilizes a plurality of LEDs coupled to a support structure that absorbs and dissipates heat generated by the LEDs without the need for a fan. The LEDs provide a uniform dose of radiation on a treatment surface over a distance range of 20 cm to 45 cm. The support structure can include a heat-conductive metal plate, ensuring efficient operation. The LEDs emit light within a range of 400 nm to 520 nm, with an output intensity of at least 30 µW/cm²/nm and at most 65 µW/cm²/nm at the treatment surface. Additionally, the device allows for adjustable power supplied to the LEDs based on various factors, including usage hours and treatment distance.
Career Highlights
Randy Schwemmin is associated with D-Rev, a company dedicated to designing innovative solutions for underserved populations. His work at D-Rev emphasizes the importance of creating accessible medical devices that can significantly impact healthcare in low-resource settings.
Collaborations
Randy has collaborated with notable colleagues such as Jayanth Chakravarthy and Krista Donaldson. Their combined expertise contributes to the development of effective medical technologies that address critical health issues.
Conclusion
Randy Schwemmin's contributions to the field of phototherapy exemplify the impact of innovation in medical technology. His patented device for treating neonatal hyperbilirubinemia showcases his commitment to improving healthcare solutions. Through his work at D-Rev and collaborations with talented individuals, Schwemmin continues to make strides in enhancing patient care.